Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
✨ Key Finding: Discontinuation of beta-blockers beyond the first year after a myocardial infarction was noninferior to continuation regarding death, recurrent MI, or heart failure hospitalization.
At subsequent visits, it’s always an opportunity to revisit [and ask] can we reduce this pill burden? This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-bl...
✨ Key Finding: Sotatercept significantly reduced pulmonary vascular resistance by 1.02 Wood units (0.3 mg/kg) and 0.75 Wood units (0.7 mg/kg) compared to placebo at 24 weeks in patients with CpcPH-HFpEF.
Similar to PAH trials, the benefits of sotatercept transcend the relatively modest reductions in resting PVR and highlight the importance of targeting inflammation, cell proliferation and endothelial function in HFpEF. As the biology of ligand traps evolves, sotatercept marks the first step in leveraging the power of signaling networks to reverse fibrosis and cellular hypertrophy. Notably, the CADENCE trial emphasizes the importance of targeting underlying biologic mechanisms responsible for disease, versus focusing solely on improving hemodynamic parameters.
✨ Key Finding: A hybrid AI adjudication approach using 30% human review correctly classified 95.6% of cardiovascular endpoints and replicated the primary treatment effect (HR 1.04 vs human HR 1.02).
✨ Key Finding: Short-term exposures to both extreme heat and cold increase the risk of major cardiovascular events, including myocardial infarction, stroke, heart failure, and sudden cardiac death.
Randomized controlled trial shows improved IRA patency in STEMI patients with heparin pretreatment, suggesting effective intervention.
✨ Key Finding: Women with pregnancy-associated spontaneous coronary artery dissection have a more severe phenotype than non-pregnancy cases, with higher STEMI incidence (18.6% vs 5.5%) and less LVEF recovery.
✨ Key Finding: Elevated serum neurofilament light chain in patients with atrial fibrillation was associated with increased major vascular events (aHR 1.35 per doubling of concentration).
✨ Key Finding: Atrial fibrillation density showed a dose-response relationship with 1-year ischemic stroke risk (RR 1.75; 95% CI 1.25-2.44), independent of overall AF burden.
✨ Key Finding: Bleeding (23.2%) and ischemic (10.5%) complications in microaxial flow pump-managed cardiogenic shock increased mortality (aHR 1.60 and 1.74), with bleeding driving a greater mortality burden.
Research uncovers the role of efferocytosis in tissue repair in the heart, indicating its importance for cardiac health.